HF
ONCY

HRT Financial’s Oncolytics Biotech ONCY Stock Holding History

HRT Financial’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19K Buy
23,256
+11,263
+94% +$11.2K ﹤0.01% 3580
2025
Q4 		$10K Sell
11,993
-7,790
-39% -$8.42K ﹤0.01% 3040
2025
Q3 		$27K Buy
+19,783
New +$22.2K ﹤0.01% 2673

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

HRT Financial's ONCY Position: Q1 2026 in Review

HRT Financial increased its Oncolytics Biotech (ONCY) stake by 94% in Q1 2026, buying an estimated $11.2K and bringing the position to 23,256 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #3580.

HRT Financial first reported a position in ONCY in Q3 2025 and has held it in 3 quarters since. The position peaked at $27K in Q3 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • HRT Financial held 23,256 shares of Oncolytics Biotech worth $19K as of Q1 2026.
  • HRT Financial bought 11,263 Oncolytics Biotech shares in Q1 2026, an estimated $11.2K.
  • Oncolytics Biotech made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3580 holding.
  • HRT Financial first reported a position in Oncolytics Biotech in Q3 2025 and has held it in 3 quarters since.
  • HRT Financial's Oncolytics Biotech position peaked at $27K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.